EFPIA Hopes To Shift Conversation In Japan From Pricing To Funding
This article was originally published in PharmAsia News
Executive Summary
The European pharma trade group also plans communication offensive on health technology assessment as Japan reconsiders pricing methodology.
You may also be interested in...
European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come
It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses
Top Japanese Pharmas Show Appetite For Emerging Market Expansion, Will Generics Follow?
TOKYO - Japanese pharma companies are trying to determine how to expand into new markets, ranging from the U.S. to China, and IMS Health data show a slow move away from dependence on the domestic market for Japan's leading companies
Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?
The new chairman of Japan's Central Social Medical Insurance Council (Chuikyo), the committee that determines drug pricing for Japan's National Health Insurance, will consider the possibility of linking drug pricing to health technology assessments, similar to the UK's National Institute for Health and Clinical Excellence